Nexalin technology announces issuance of u.s. patent covering halo™ clarity device featuring difs™ technology

Houston, tx, sept. 25, 2025 (globe newswire) -- nexalin technology, inc. (nasdaq: nxl; nxliw) (the “company” or “nexalin”), the leader in deep intracranial frequency stimulation (difs™) of the brain, today announced that the united states patent and trademark office (uspto) has issued u.s. design patent no. d1,092,758, entitled transcranial electro-stimulation device, providing 15 years of design protection for the company's next-generation halo™ clarity neuromodulation device.
NXL Ratings Summary
NXL Quant Ranking